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Introduction {#sec1}
============

The innate immune system provides a rapid initial defense program against invading pathogens that relies on the recognition of pathogen-associated molecular patterns (PAMPs) to shape local immune responses. Innate immune activation can also be observed in the absence of infection, following the detection of danger-associated molecular patterns (DAMPs) after injury or during sterile inflammation. PAMPs and DAMPs are detected by pattern recognition receptors, which then induce the production of interferons, cytokines, and chemokines. Intracellular DNA receptors recognize double-stranded (ds) DNA as a PAMP during infection with DNA viruses and other intracellular pathogens but can also detect self-DNA as a DAMP under some circumstances, for instance, when damaged DNA has leaked into the cytosol (reviewed by [@bib12]). The key DNA sensor in the cytosol is cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS), which catalyzes the synthesis of the second messenger cyclic GMP-AMP (cGAMP) (reviewed by [@bib8]). cGAMP then binds to the DNA sensing adaptor STING at the endoplasmic reticulum (ER), causing a conformational change associated with the activation of STING dimers ([@bib6]). In addition to the conformational change caused by cGAMP binding, STING function is regulated by phosphorylation, palmitoylation, sumoylation, and modification with K63-, K48-, K27-, and K11-linked poly-ubiquitin chains ([@bib9], [@bib25], [@bib40]). Following its activation, STING translocates from the ER to signaling compartments, where STING associates with the kinase TBK1, which mediates the activation of the transcription factor interferon regulatory factor 3 (IRF3) and, to a lesser extent, nuclear factor κB (NF-κB) ([@bib1], [@bib13], [@bib32]). Both IRF3 and NF-κB are required for the expression of interferon-β (*IFN-β*) mRNA.

cGAS-mediated STING activation is crucial for the detection of DNA from intracellular pathogens. In human monocytes and keratinocytes, STING activation by cGAS requires the cooperation with the DNA binding protein IFI16 (interferon-γ-inducible factor 16), which shuttles between the nucleus and the cytosol but is nuclear at steady state ([@bib3], [@bib27], [@bib30], [@bib47]). cGAS can also detect DNA damage in a process involving mitotic progression, the formation of micronuclei and leakage of DNA into the cytosol, which occurs several days after recovery from DNA damage ([@bib14], [@bib18], [@bib20], [@bib35]).

dsDNA breaks are also known to induce a more rapid innate immune response that involves the activation of NF-κB (reviewed by [@bib37]). The transcription factor NF-κB promotes cell survival and can induce the expression of a variety of cytokines and chemokines. DNA damage-induced NF-κB activation can influence tumor progression and clearance of tumor cells by the immune system after radio- or chemotherapy (reviewed by [@bib22]). NF-κB activation occurs within the first hours following the detection of double-strand breaks and involves the DNA damage kinase ataxia telangiectasia mutated (ATM) and the enzyme poly(ADP-ribose) polymerase 1 (PARP-1) ([@bib23], [@bib42], [@bib43]). ATM and PARP-1 detect double-strand breaks in the nucleus and signal inside out to activate a cytosolic signaling complex containing the E3 ubiquitin ligase TRAF6, TAK1, TAB2/3, and the NF-κB inhibitor (IκB) kinase complex (IKKα, IKKβ, and NEMO) ([@bib23], [@bib43], [@bib51]). ATM-dependent NF-κB activation has been observed in response to ionizing radiation, replication stress, and topoisomerase poisons such as etoposide (reviewed by [@bib37]).

We find that etoposide treatment induces an NF-κB-dependent innate immune response within hours of treatment, which is particularly potent in human keratinocytes. This response involves ATM and PARP-1, as well as the DNA sensing factors IFI16 and STING, but is independent of cGAS and cGAMP production. Etoposide-induced DNA damage results in a non-canonical mode of STING activation, causing the assembly of an alternative STING-containing signaling complex. This leads to the predominant activation of NF-κB, rather than IRF3, and the induction of an innate immune gene expression profile that differs from that induced by cytosolic DNA sensing. We propose that alternative modes of STING activation shape the innate immune response, depending on the type of threat.

Results {#sec2}
=======

Etoposide-Induced DNA Damage Causes an Acute Cell-Intrinsic Innate Immune Response in Human Cells {#sec2.1}
-------------------------------------------------------------------------------------------------

We tested the cell-intrinsic response to DNA damage in human keratinocytes, which, in the outermost layer of our skin, are the first point of contact for many pathogens and are exposed to physical and chemical insults from sunlight or environmental toxins. We find that following treatment with the topoisomerase II poison etoposide, immortalized human HaCaT keratinocytes induce an acute innate immune response that involves the expression of *IFN-β*, the cytokine interleukin-6 (*IL-6*), and the chemokine *CCL20* ([Figures 1](#fig1){ref-type="fig"}A--1C). mRNA induction was apparent from 4 hr of treatment and peaking after 8--12 hr ([Figures 1](#fig1){ref-type="fig"}A--1C). We also detected the secretion of active type I IFN ([Figure 1](#fig1){ref-type="fig"}D) and the subsequent induction of interferon-stimulated genes such as *IRF7* and *IFI16* as a consequence of type I IFN signaling ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Etoposide treatment also caused the secretion of IL-6 protein ([Figure 1](#fig1){ref-type="fig"}E). The transcriptional response to DNA damage correlated with the phosphorylation of histone γH2A.X ([Figure 1](#fig1){ref-type="fig"}F) and occurred at time points at which etoposide treatment had not yet caused significant cell death and only a small fraction of cells displayed early signs of apoptosis by Annexin V staining ([Figures 1](#fig1){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}C).Figure 1Etoposide-Mediated DNA Damage Induces an Acute Innate Immune Response in Human Cells(A--C) HaCaT keratinocytes were treated with 50 μM etoposide for the times indicated before qRT-PCR analysis of *IFN-β* (A), *IL-6* (B), and *CCL20* (C) mRNA.(D and E) Supernatants from cells treated with 50 μM etoposide were analyzed for secreted type I IFN using a bio-assay (D) or IL-6 protein using ELISA (E).(F) HaCaT cells were treated with 50 μM etoposide for the times indicated or transfected with 1 μg/mL herring testis (HT)-DNA for 6 hr. Phosphorylation of γH2A.X was analyzed by immunoblotting.(G) Cytotoxicity assay of HaCaT cells treated with 50 μM etoposide for the times indicated or lysed (Lys).(H and I) Primary normal human epidermal keratinocytes (NHEKs) from adult donors were treated with 50 μM etoposide for the times indicated before qRT-PCR analysis of *IFN-β* (H) and *IL-6* (I) mRNA.(J) Supernatants from NHEK cells treated as in (H) were analyzed for IL-6 secretion by ELISA.(K) Cytotoxicity assay of NHEK cells treated as in (H) or lysed (Lys).(L) Primary MRC-5 fibroblasts were treated with 50 μM etoposide before qRT-PCR analysis of IFN-β mRNA expression.(M) Cytotoxicity assay of MRC-5 cells treated with 50 μM etoposide or lysed (Lys).(N) PMA-differentiated THP1 cells were stimulated with 50 μM etoposide for indicated times before qRT-PCR analysis of *IFN-β* mRNA.(O) Cytotoxicity assay of THP1 cells treated as in (N) or lysed (Lys).Data are presented as mean values of biological triplicates ± SD. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We detected a similar innate immune response to DNA damage in primary normal human epidermal keratinocytes (NHEKs) from adult donors, involving the expression of *IFN-β*, *IL-6*, and *CCL20* mRNA ([Figures 1](#fig1){ref-type="fig"}H, 1I, and [S1](#mmc1){ref-type="supplementary-material"}D) and secretion of IL-6 protein ([Figure 1](#fig1){ref-type="fig"}J) at time points at which etoposide treatment did not cause detectable amounts of cell death ([Figure 1](#fig1){ref-type="fig"}K). An etoposide-induced innate immune response was also detectable in other cell types, even though the response was more modest in MRC-5 primary human embryonic fibroblasts ([Figures 1](#fig1){ref-type="fig"}L, 1M, and [S1](#mmc1){ref-type="supplementary-material"}E--S1G) and started at later time points, after 24--36 hr, in human THP1 monocytes, whether or not they had been differentiated using phorbol 12-myristate 13-acetate (PMA) ([Figures 1](#fig1){ref-type="fig"}N, 1O, and [S1](#mmc1){ref-type="supplementary-material"}H--S1L).

The Innate Immune Response to Etoposide-Induced DNA Damage Involves the DNA Sensing Adaptor STING {#sec2.2}
-------------------------------------------------------------------------------------------------

We tested whether the DNA sensing adaptor STING is involved in the acute innate immune response to etoposide-induced double-strand breaks. HaCaT keratinocytes lacking STING still expressed cGAS and IFI16, displayed unaltered γH2A.X phosphorylation ([Figure 2](#fig2){ref-type="fig"}A), and are able to survive as well as wild-type cells after etoposide treatment ([Figure 2](#fig2){ref-type="fig"}B). However, STING-deficient cell clones were unable to induce the transcription of *IFN-β* mRNA after etoposide treatment ([Figure 2](#fig2){ref-type="fig"}C). As expected, STING-deficient cells were also impaired in their response to transfected DNA but supported *IFN-β* mRNA induction in response to the dsRNA mimic poly(I:C) ([Figure 2](#fig2){ref-type="fig"}C). The lack of STING also impaired *IL-6* mRNA expression and IL-6 protein secretion in response to etoposide treatment or DNA transfection, but not following transfection with poly(I:C) ([Figures 2](#fig2){ref-type="fig"}D and 2E).Figure 2STING Is Required for the Innate Immune Response to Etoposide-Induced DNA Damage(A) Wild-type (WT) and *STING*^−/−^ HaCaT cells were treated with DMSO or 50 μM etoposide for 6 hr, and protein expression was analyzed by immunoblotting.(B) Clonogenic survival assay of WT and *STING*^−/−^ HaCaT cells. Numbers of colonies \> 50 cells were counted and expressed as a percentage of untreated control.(C and D) WT HaCaT and two STING^−/−^ clones were treated with DMSO or 50 μM etoposide, mock transfected (Lipo), or transfected with 1 μg/mL HT-DNA or 100 ng/mL poly(I:C) for 6 hr before qRT-PCR analysis of *IFN-β* (C) and *IL-6* (D) mRNA expression.(E) ELISA analysis of IL-6 secretion in supernatants from cells treated as in (C) for 24 hr.(F) qRT-PCR array analysis of cytokine and chemokine expression in WT and *STING*^−/−^ HaCaT cells treated with DMSO, 50 μM etoposide, Lipofectamine, or 1 μg/mL HT-DNA for 6 hr. Shown are genes induced at least 2-fold over controls.(G and H) WT and *STING*^−/−^ HaCaT cells grown on coverslips were treated with 50 μM etoposide for 4 hr and stained for NF-κB p65 (green) and DNA (DAPI, blue) for analysis by confocal microscopy (G) and quantification of p65 nuclear translocation (H). Scale bar, 20 μm.(I and J) NHEKs were treated with non-targeting (NT) or *STING*-targeting siRNA pools for 48 hr before treatment with 50 μM etoposide for 24 hr. STING protein levels were analyzed by immunoblotting (I), and *IFN-β* mRNA expression was quantified by qRT-PCR (J).(K) MRC-5 fibroblasts were treated with non-targeting (NT) or *STING*-targeting siRNA pools for 48 hr before treatment with 50 μM etoposide for 6 hr and analysis of *IFN-β* mRNA by RT-PCR.(L) PMA-differentiated WT and *STING*^−/−^ THP1 cells were stimulated with 50 μM etoposide for 30 hr or 1 μg/mL HT-DNA for 6 hr before qRT-PCR analysis of *IFN-β* mRNA.Data are presented as mean values of biological triplicates ± SD. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}A--S3F.

Despite the involvement of STING in both the response to exogenous DNA and the response to DNA damage, the pattern of innate immune gene induction differed between the two stimuli. Etoposide treatment induced higher levels of *IL-6* and *CCL20* mRNA and lower levels of the chemokine *CXCL10* and the IRF3-responsive gene ISG56 than DNA transfection under conditions for which *IFN-β* mRNA induction is comparable ([Figures 2](#fig2){ref-type="fig"}C, 2D, and [S2](#mmc1){ref-type="supplementary-material"}A--S2C). Transcription factor activation profiles also differed between the two responses, with the response to DNA damage involving prominent nuclear translocation of the NF-κB subunit p65 and only modest activation of IRF3 ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2G). We used a PCR array to quantify the expression of more than 80 cytokines and chemokines in HaCaT cells treated with etoposide or transfected DNA for 4 hr. We found that even though the two stimuli induced different cytokine expression profiles, both responses were STING dependent ([Figure 2](#fig2){ref-type="fig"}F). The STING-dependent response to etoposide included the expression of genes such as CCL20, which is not strongly induced by conventional DNA-induced STING signaling ([Figures 2](#fig2){ref-type="fig"}F, [S2](#mmc1){ref-type="supplementary-material"}C, and [S3](#mmc1){ref-type="supplementary-material"}A). HaCaT cells lacking STING were also unable to support etoposide-induced NF-κB p65 nuclear translocation or phosphorylation ([Figures 2](#fig2){ref-type="fig"}G, 2H, and [S3](#mmc1){ref-type="supplementary-material"}B), as well as TBK1 and IRF3 phosphorylation induced by DNA transfection ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

We confirmed the requirement for STING in the innate immune response to double-strand breaks using RNAi in primary NHEKs ([Figures 2](#fig2){ref-type="fig"}I, 2J, and [S3](#mmc1){ref-type="supplementary-material"}C), in MRC-5 fibroblasts ([Figures 2](#fig2){ref-type="fig"}K, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E), and in THP1 cells lacking STING ([Figures 2](#fig2){ref-type="fig"}L and [S3](#mmc1){ref-type="supplementary-material"}F). We conclude that the acute innate immune response to etoposide-induced double-strand breaks involves the STING-mediated activation of NF-κB p65 and the induction of a non-canonical STING-dependent innate immune gene expression program.

IFI16 Is Required for the Etoposide-Induced Innate Immune Response {#sec2.3}
------------------------------------------------------------------

IFI16 is a DNA binding protein that cooperates with cGAS in the detection of cytosolic DNA in human keratinocytes and macrophages ([@bib3], [@bib27]). IFI16 has also been described as a tumor suppressor protein, which associates with DNA damage factors such as BRCA1 and p53 and acts to promote cellular senescence ([@bib2], [@bib11], [@bib26]). Due to its predominantly nuclear localization, we hypothesized that IFI16 may be a good candidate to provide a link between DNA damage and innate immunity when the cell's own damaged DNA may be sensed as a DAMP.

IFI16-deficient HaCaT cells were able to support γH2A.X phosphorylation after etoposide treatment ([Figure 3](#fig3){ref-type="fig"}A) and displayed a survival advantage over wild-type cells in clonogenic survival assays ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Like STING-deficient cells, two independent HaCaT cell clones lacking IFI16 were unable to induce the expression of *IFN-β* mRNA after etoposide treatment ([Figure 3](#fig3){ref-type="fig"}B). As observed previously ([@bib3]), the response to exogenous DNA was also reduced in cells lacking IFI16, while poly(I:C)-induced *IFN-β* mRNA expression was unaffected ([Figure 3](#fig3){ref-type="fig"}B). The etoposide-induced secretion of bio-active type I interferons was also impaired in cells lacking IFI16 ([Figure S3](#mmc1){ref-type="supplementary-material"}H), as was the expression of *IL-6* mRNA, the secretion of IL-6 protein, and the expression of *CCL20* mRNA ([Figures 3](#fig3){ref-type="fig"}C--3E). IFI16 was also required for the phosphorylation and nuclear translocation of NF-κB following etoposide treatment ([Figures 3](#fig3){ref-type="fig"}F--3H).Figure 3The Innate Immune Response to Etoposide-Induced Damage Involves IFI16(A) Immunoblotting analysis of WT and *IFI16*^−/−^ HaCaT cells stimulated with 50 μM etoposide or DMSO for 6 hr.(B and C) WT HaCaT cells and two *IFI16*^−/−^ cell clones were treated for 6 hr with DMSO or 50 μM etoposide, mock transfected (Lipo), or transfected with 1 μg/mL HT-DNA or 100 ng/mL poly(I:C). *IFN-β* (B) or *IL-6* (C) mRNA was quantified by qRT-PCR.(D) ELISA analysis of IL-6 protein in supernatants from WT and *IFI16*^−/−^ HaCaT cells treated with 50 μM etoposide for indicated times.(E) qRT-PCR analysis of *CCL20* mRNA in WT and *IFI16*^−/−^ HaCaT cells treated with DMSO or 50 μM etoposide for 6 hr.(F) WT and *IFI16*^−/−^ HaCaT cells were treated as in (B) for 4 hr before analysis of protein expression by immunoblotting.(G) WT and *IFI16*^−/−^ HaCaT cells grown on coverslips were treated with 50 μM etoposide for 4 hr and fixed and stained for p65 (green) and DNA (DAPI, blue). Scale bar, 20 μm.(H) Quantification of p65 nuclear translocation in cells from (G).(I) Immunoblotting analysis of WT HaCaT cells and *IFI16*^−/−^ HaCaT cells reconstituted with lentiviruses for the expression of Luciferase (luc) or IFI16 as indicated. Cells were treated with doxycycline for 24 hr to induce expression and then stimulated with 50 μM etoposide for 6 hr.(J) qRT-PCR analysis of *IFN-β* mRNA in cells treated as in (I) as indicated.(K--M) MRC-5 fibroblasts treated with non-targeting (NT) or *IFI16*-targeting siRNA pools for 48 hr before treatment with 50 μM etoposide or DMSO for 6 hr. IFI16 protein expression was analyzed by immunoblotting (K). *IFN-β* (L) and *IL-6* (M) mRNA levels were analyzed by qRT-PCR.Data are presented as mean values of biological triplicates ± SD. See also [Figures S3](#mmc1){ref-type="supplementary-material"}G--S3L.

We confirmed the involvement of IFI16 in the DNA damage-induced innate immune response by reconstituting *IFI16*^−/−^ HaCaT cells with lentivirus for the inducible expression of IFI16 or Luciferase as control. IFI16 re-expression rescued DNA damage-induced *IFN-β* expression ([Figures 3](#fig3){ref-type="fig"}I and 3J). The role of IFI16 was confirmed in MRC-5 fibroblasts ([Figures 3](#fig3){ref-type="fig"}K--3M and [S3](#mmc1){ref-type="supplementary-material"}I) and in primary NHEKs ([Figures S3](#mmc1){ref-type="supplementary-material"}J--S3L) using RNAi.

The Acute Innate Immune Response to Etoposide-Induced Damage Is Independent of cGAS and cGAMP {#sec2.4}
---------------------------------------------------------------------------------------------

Because IFI16 cooperates with cGAS in the activation of STING, we tested whether cGAS was also required for the early innate immune response following etoposide treatment. cGAS-deficient HaCaT cell clones were still able to support γH2A.X phosphorylation after etoposide treatment ([Figure 4](#fig4){ref-type="fig"}A). However, in contrast to the data obtained with IFI16- or STING-deficient cells, cGAS was dispensable for *IFN-β* mRNA induction after etoposide treatment, even though cGAS was essential for *IFN-β* expression after DNA transfection, as expected ([Figure 4](#fig4){ref-type="fig"}B). cGAS was also dispensable for the induction of *IL-6* and *CCL20* mRNA after etoposide treatment ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}A) and the secretion of IL-6 protein measured by ELISA ([Figure 4](#fig4){ref-type="fig"}D).Figure 4cGAS Is Dispensable for the Early Innate Immune Response to Nuclear DNA Damage(A) Immunoblotting analysis of WT and two *cGAS*^−/−^ HaCaT clones treated with DMSO or 50 μM etoposide for 6 hr.(B and C) WT and *cGAS*^−/−^ HaCaT cells were treated with DMSO or 50 μM etoposide, mock transfected (Lipo), or transfected with 1 μg/mL HT-DNA or 100 ng/mL poly(I:C) for 6 hr before qRT-PCR analysis of *IFN-β* (B) and *IL-6* (C) mRNA expression.(D) IL-6 in supernatants from WT and *cGAS*^−/−^ HaCaT cells treated with 50 μM etoposide quantified by ELISA.(E) MRC-5 fibroblasts were treated with non-targeting (NT) or *cGAS*-targeting siRNA pools for 48 hr before treatment with 50 μM etoposide for 6 hr. cGAS protein expression was analyzed by western blot.(F) qRT-PCR analysis of *IFN-β* mRNA expression in MRC-5 fibroblasts treated with siRNA as in (E) and stimulated with 50 μM etoposide or transfected with 1 μg/mL HT-DNA for 6 hr.(G) PMA-differentiated WT, *cGAS*^−/−^, and *IFI16*^−/−^ THP1 cells were treated with 50 μM etoposide for 30 hr or 1 μg/mL HT-DNA for 6 hr before qRT-PCR analysis of *IFN-β* mRNA.(H) WT and *cGAS*^−/−^ HaCaT cells grown on coverslips were treated with 50 μM etoposide for 4 hr, stained for p65 (green) and DNA (DAPI, blue), and visualized by confocal microscopy. Scale bar, 20 μm.(I) Quantification of p65 translocation from (H).(J) HaCaT cells were treated with 50 μM etoposide for the indicated times or transfected with 1 μg/mL HT-DNA for 4 hr. cGAMP production was quantified by LC-MS.Data are presented as mean values of biological triplicates ± SD. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To exclude potential off-target effects or compensatory mechanisms that may have arisen during the generation of cGAS-deficient cell clones, we confirmed the differential roles of cGAS using RNAi in HaCaT keratinocytes ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and in MRC-5 fibroblasts ([Figures 4](#fig4){ref-type="fig"}E and 4F). Etoposide-induced IFN-β mRNA expression was impaired in IFI16-deficient THP1 cells, but not cGAS-deficient THP1 cells ([Figure 4](#fig4){ref-type="fig"}G), while the response to transfected DNA required the cooperation of both proteins, as described ([@bib27]). In agreement with the gene expression data, the absence of cGAS did not affect etoposide-induced NF-κB p65 translocation to the nucleus ([Figures 4](#fig4){ref-type="fig"}H and 4I).

Non-conventional STING Activation after DNA Damage {#sec2.5}
--------------------------------------------------

During the detection of cytosolic DNA, STING is activated by binding the second messenger cGAMP, which causes a conformational change in the STING dimer ([@bib17]). Given that cGAS was not required for the early innate immune response to DNA damage, we tested the possibility that another enzyme in the cell may substitute for cGAS function. We measured the production of endogenous cGAMP in HaCaT cells using a liquid chromatography-mass spectrometry (LC-MS) approach, which allowed us to specifically quantify cGAMP, using c-di-AMP as spike-in control to account for variations arising from sample processing ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). Unlike DNA transfection, Etoposide treatment did not cause any increase in cGAMP production above basal levels ([Figures 4](#fig4){ref-type="fig"}J and [S4](#mmc1){ref-type="supplementary-material"}E). This demonstrates that the function of STING during the response to nuclear DNA damage involves its non-canonical activation in a cGAS- and cGAMP-independent manner.

During conventional DNA sensing, STING translocates from the ER to peri-nuclear foci and gets phosphorylated by TBK1 at Serine 366 ([@bib13], [@bib32]). Etoposide treatment did not cause any detectable STING phosphorylation ([Figure S5](#mmc1){ref-type="supplementary-material"}A) or STING translocation to characteristic foci ([Figure 5](#fig5){ref-type="fig"}A). To test whether STING translocation is dispensable or whether some low level of translocation occurs, which is not apparent by confocal microscopy, we inhibited STING translocation using brefeldin A ([Figure 5](#fig5){ref-type="fig"}A). Pre-treatment with brefeldin A inhibited the expression of *IFN-β* in response to both etoposide treatment and DNA transfection ([Figure 5](#fig5){ref-type="fig"}B). However, although *IL-6* mRNA expression after DNA transfection also required STING trafficking, trafficking was not required for DNA damage-induced *IL-6* expression ([Figure 5](#fig5){ref-type="fig"}C). Similar results were obtained with a TBK1 inhibitor ([@bib10]), which impaired etoposide-induced *IFN-β* mRNA expression, but not *IL-6* expression ([Figures 5](#fig5){ref-type="fig"}D and 5E), while both *IFN-β* and *IL-6* mRNA expression were TBK1 dependent in response to cytosolic DNA, as described ([@bib1]). TBK1 function was also dispensable for the etoposide-induced nuclear translocation of NF-κB p65 ([Figures 5](#fig5){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}B). This suggests that low levels of STING trafficking and TBK1 activation must occur after etoposide-induced damage and contribute to the induction of *IFN-β* mRNA under these conditions. The expression of NF-κB-dependent genes such as *IL-6*, however, proceeds independently of STING trafficking and TBK1 activity.Figure 5Etoposide-Induced NF-κB Activation Involves DNA Damage Factors, but Not TBK1 Activity(A) HaCaT cells grown on coverslips were pre-treated for 30 min with 3 μg/mL brefeldin A where indicated before stimulation with 50 μM etoposide or transfection of 1 μg/mL HT-DNA. Cells were fixed and stained for STING (green) and DNA (DAPI, blue). Scale bar, 20 μm.(B and C) HaCaT cells were pre-treated for 30 min with 3 μg/mL brefeldin A before treatment with 50 μM etoposide or DMSO, mock transfection (Lipo), or transfection of 1 μg/mL HT-DNA for 6 hr. *IFN-β* (B) and *IL-6* (C) mRNA expression was analyzed by qRT-PCR.(D and E) HaCaT cells were pre-treated for 1 hr with 2 μM TBK1 inhibitor MRT67307 and stimulated as in (B) before qRT-PCR analysis of *IFN-β* (D) and *IL-6* (E) mRNA expression.(F) HaCaT cells grown on coverslips were pre-treated with 2 μM TBK1 inhibitor MRT67307 for 1 hr before 4 hr of stimulation with 50 μM etoposide. Cells were fixed and stained for p65 (red) and DNA (DAPI, blue). Scale bar, 20 μm.(G and H) HaCaT cells were pre-treated for 1 hr with 10 μM ATM inhibitor KU55933 and stimulated as in (B). *IFN-β* (G) and *IL-6* (H) mRNA expression was quantified by qRT-PCR.(I) ELISA analysis of IL-6 secretion in supernatants from cells treated as in (G) and stimulated for 24 hr.(J) HaCaT cells grown on coverslips were pre-treated for 1 hr with 10 μM KU55933 before 4 hr of stimulation with 50 μM etoposide. Cells were fixed and stained for p65 (green) and DNA (DAPI, blue). Scale bar, 20 μm.(K) qRT-PCR analysis of IFN-β mRNA expression in NHEK cells pre-treated for 1 hr with 10 μM KU55933, followed by treatment with 50 μM etoposide for 24 hr.(L) qRT-PCR analysis of *IFN-β* mRNA in HaCaT cells pre-treated for 1 hr with 10 μM PARP inhibitor PJ34 before treatment as in (B) for 6 hr.Data are presented as mean values of biological triplicates ± SD. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

The DNA Damage Factors ATM and PARP-1 Are Required for the Innate Immune Response to Double-Strand Breaks {#sec2.6}
---------------------------------------------------------------------------------------------------------

The early activation of NF-κB in response to double-strand breaks has been shown to involve the DNA damage kinase ATM and PARP-1 ([@bib23], [@bib37], [@bib43], [@bib51]). Thus, we tested whether these factors are also involved in the STING-dependent innate immune response to DNA damage that we observe in human keratinocytes. We found that inhibition of ATM impaired the expression of *IFN-β* and *IL-6* mRNA after DNA damage and the secretion of IL-6 protein in HaCaT keratinocytes ([Figures 5](#fig5){ref-type="fig"}G--5I). ATM activity was not required for the induction of *IFN-β* and *IL-6* following DNA transfection ([Figures 5](#fig5){ref-type="fig"}G--5I), highlighting the differences between these two STING-dependent responses. ATM was also required for the nuclear translocation of NF-κB p65 ([Figures 4](#fig4){ref-type="fig"}J and [S5](#mmc1){ref-type="supplementary-material"}C) and p65 phosphorylation after etoposide treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}D). A role for ATM was confirmed in NHEK ([Figures 5](#fig5){ref-type="fig"}K, [S5](#mmc1){ref-type="supplementary-material"}E, and S5F) and in MRC-5 fibroblasts ([Figures S5](#mmc1){ref-type="supplementary-material"}G--S5I). Like ATM, PARP-1 was also specifically required for the induction of *IFN-β* and *IL-6* expression in response to nuclear DNA damage but was dispensable for the detection of cytosolic DNA ([Figures 5](#fig5){ref-type="fig"}L and [S5](#mmc1){ref-type="supplementary-material"}J).

ATM-Dependent Assembly of a Non-canonical Signaling Complex Containing STING {#sec2.7}
----------------------------------------------------------------------------

After detection of nuclear double-strand breaks, ATM and PARP-1 signal inside out to activate TRAF6 and the IKK complex in the cytosol ([@bib37]). ATM also phosphorylates p53, which has been shown to interact with IFI16 ([@bib31]). To investigate whether non-canonical activation of STING involves these factors, we interrogated STING complex assembly using immunoprecipitation of endogenous STING in etoposide-treated HaCaT cells. We found that the interaction between IFI16 and STING increased transiently after etoposide treatment and p53 and TRAF6 assemble on STING within 30 min and 1 hr of etoposide treatment, respectively ([Figure 6](#fig6){ref-type="fig"}A). This complex is specifically induced by DNA damage and does not form when STING is activated by DNA transfection ([Figure 6](#fig6){ref-type="fig"}B). Complex formation requires the function of both PARP-1 and ATM ([Figures 6](#fig6){ref-type="fig"}C and 6D). The DNA damage-induced STING complex likely forms at the ER where STING resides, because p53, IFI16, and TRAF6 all shuttle between nucleus and cytosol and become enriched in the membrane fraction of cells after etoposide treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}A).Figure 6Nuclear DNA Damage Results in the Assembly of a Non-canonical Signaling Complex Containing STING(A) Immunoprecipitation of STING from HaCaT cells treated with 50 μM etoposide for the indicated times. Immunoprecipitates (IPs) and whole-cell lysates were analyzed by immunoblotting.(B) Immunoblotting analysis following immunoprecipitation of STING from HaCaT cells treated with 50 μM etoposide or transfected with 1 μg/mL HT-DNA as indicated.(C) Immunoprecipitation of STING from HaCaT cells pre-treated for 1 hr with 10 μM PARP inhibitor PJ34, followed by treatment with 50 μM etoposide for 2 hr.(D) Immunoprecipitation of STING from HaCaT cells pre-treated for 1 hr with 10 μM ATM inhibitor KU55933 followed by treatment with 50 μM etoposide.(E) Immunoprecipitation of STING from WT and *IFI16*^−/−^ HaCaT cells treated with 50 μM etoposide as indicated.(F) Immunoprecipitation of IFI16 from WT and *STING*^−/−^ HaCaT cells treated with 50 μM etoposide as indicated.(G) HEK293T cells transfected with expression constructs for IFI16 and WT p53 or the S15A or S15D p53 mutants as indicated. 24 hr after transfection, IFI16 was immunoprecipitated from lysates.(H) p53 protein levels in HaCaT cells transfected with a non-targeting (NT) or a *p53*-targeting siRNA pool for 48 hr before stimulation with 50 μM etoposide for 6 hr.(I) qRT-PCR analysis of *IL-6* mRNA expression in cells treated as in (H).See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Both IFI16 and p53 assemble on STING soon after etoposide treatment, and interaction between p53 and IFI16 has been shown to be direct ([@bib31]). Using IFI16-deficient HaCaT cells, we observed that IFI16 was required for the recruitment of p53 to STING ([Figure 6](#fig6){ref-type="fig"}E), while the absence of STING still permitted the IFI16-p53 interaction ([Figure 6](#fig6){ref-type="fig"}F). This suggests that IFI16 forms a complex with p53 and delivers it to STING after DNA damage, in a manner that depends on ATM activity. ATM phosphorylates p53 at several residues, including Serine 15 (Ser15), which results in the activation of p53 ([@bib4], [@bib7]). To assess the role of p53 Ser15 phosphorylation in complex assembly, we co-expressed IFI16 and p53 in HEK293T cells, using wild-type p53 or an alanine mutant at position 15 (15A), which cannot be phosphorylated, or using a mutant for which Ser15 is substituted with aspartate (15D), which acts as a phospho-mimic ([@bib33]). Only wild-type p53 and the 15D phospho-mimic were able to interact with IFI16; the 15A mutant was unable to do so ([Figure 6](#fig6){ref-type="fig"}G). A similar pattern was observed for the interaction between p53 and STING ([Figure S6](#mmc1){ref-type="supplementary-material"}B), demonstrating that p53 phosphorylation at Ser15 is a requirement for complex formation.

This association of p53 to the STING complex was functionally important for the innate immune response to DNA damage, because p53 depletion by small interfering RNA (siRNA) impaired the expression of *IL-6*, *IFN-β*, and *CCL20* in HaCaT keratinocytes ([Figures 6](#fig6){ref-type="fig"}H, 6I, [S6](#mmc1){ref-type="supplementary-material"}C, and S6D). HaCaT cells are spontaneously immortalized and express mutated forms of p53, which are partially functional, but may also have acquired additional functions ([@bib5], [@bib28]). Thus, we tested p53 function in primary human MRC-5 fibroblasts that express wild-type p53. We found a similar p53 dependence of etoposide-induced *IFN-β* expression in fibroblasts ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F). Altogether, our data show that phosphorylation of p53 at Ser15 likely provides a link between ATM activity and assembly of a STING-containing innate immune signaling complex.

TRAF6 Mediates STING-Dependent NF-κB Activation after DNA Damage {#sec2.8}
----------------------------------------------------------------

We next investigated the role of TRAF6 in the STING complex. We found that TRAF6 transiently interacted with IFI16 in etoposide-treated HaCaT cells, and IFI16 was required for the etoposide-induced recruitment of TRAF6 to the STING complex ([Figure 7](#fig7){ref-type="fig"}A). TRAF6 has an important function in this response, because two TRAF6-deficient HaCaT cell clones were able to support γH2A.X phosphorylation after etoposide treatment ([Figure 7](#fig7){ref-type="fig"}B) but were impaired in their ability to induce *IL-6*, *IFN-β*, and *CCL20* mRNA after DNA damage, while the response to exogenous DNA was unaffected ([Figures 7](#fig7){ref-type="fig"}C, 7D, and [S7](#mmc1){ref-type="supplementary-material"}A).Figure 7TRAF6 Mediates the K63-Linked Poly-ubiquitylation of STING(A) Immunoprecipitation of TRAF6 and STING from WT and *IFI16*^−/−^ HaCaT cells treated with 50 μM etoposide as indicated. Immunoprecipitates (IP) with immunoglobulin G (IgG) control and input lysates were analyzed by immunoblotting.(B) WT and two *TRAF6*^−/−^ HaCaT clones were treated with 50 μM etoposide for 6 hr, and protein expression was analyzed by immunoblotting.(C) qRT-PCR analysis of *IL-6* mRNA expression in cells treated as in (B).(D) WT and *TRAF6*^−/−^ HaCaT cells were treated with 50 μM etoposide or DMSO, mock transfected (Lipo), or transfected with 1 μg/mL HT-DNA for 6 hr before qRT-PCR analysis of *IFN-β* mRNA.(E) Immunoblotting analysis of WT and *TRAF6*^−/−^ HaCaT cells treated with 50 μM etoposide for the indicated times.(F) HaCaT cells were pre-treated for 1 hr with the indicated concentrations of Ubc13 inhibitor NSC697923 (NSC) before 6 hr of stimulation with 50 μM etoposide. *IL-6* mRNA expression was quantified by qRT-PCR.(G) HEK293T cells were transfected with plasmids for the expression of IFI16, FLAG-tagged TRAF6, and hemagglutinin (HA)-tagged ubiquitin as indicated. 24 hr after transfection, STING was immunoprecipitated, and proteins in immunoprecipitates and input lysates were analyzed by immunoblotting.(H) Immunoprecipitation of K63-linked ubiquitin chains from WT and *TRAF6*^−/−^ HaCaT cells treated with 50 μM etoposide for the times indicated. Higher molecular weight forms of modified STING are visualized by gradient SDS-PAGE above the antibody heavy chain (^∗^), top panel, together with the association of unmodified STING, lower panel.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

TRAF6 is a component of many innate immune signaling complexes, where it catalyzes the formation of K63-linked ubiquitin chains, which then mediate the recruitment of TAB2/3 and TAK1, leading to activation of the IKK complex and phosphorylation of NF-κB p65 ([@bib48]). We also observe TRAF6-dependent TAK1 and p65 phosphorylation after DNA damage ([Figure 7](#fig7){ref-type="fig"}E). Inhibition of the E2 enzyme Ubc13, which works with TRAF6 to catalyze K63-linked ubiquitin chain formation, impaired the etoposide-induced expression of *IL-6*, *IFN-β*, and *CCL20* ([Figures 7](#fig7){ref-type="fig"}F, [S7](#mmc1){ref-type="supplementary-material"}B, and S7C), showing that the assembly of K63-linked ubiquitin chains is an important feature of this response.

TRAF6, but not TRAF2 or TRAF3, was able to cause the assembly of ubiquitin chains on a STING complex when overexpressed ([Figure S7](#mmc1){ref-type="supplementary-material"}D), and this function was enhanced in the presence of IFI16 ([Figure 7](#fig7){ref-type="fig"}G). The TRAF6-dependent K63-linked ubiquitylation of endogenous STING could be observed in HaCaT cells within 1 hr of etoposide treatment ([Figure 7](#fig7){ref-type="fig"}H), and unmodified STING transiently associated with a complex containing K63-linked ubiquitin chains in a TRAF6-dependent manner ([Figure 7](#fig7){ref-type="fig"}H). We conclude that the IFI16-mediated recruitment of TRAF6 to a DNA damage-induced STING complex leads to the assembly of K63-linked ubiquitin chains on STING, promoting the activation of NF-κB after nuclear DNA damage.

Discussion {#sec3}
==========

In this work, we describe a non-canonical mode of STING activation, which results in the induction of an acute innate immune response within hours of etoposide-induced damage. This cell-intrinsic response is distinct from the delayed response due to the detection of DNA from cytosolic micronuclei, which involves cGAS and STING ([@bib14], [@bib18], [@bib20], [@bib35]). The early response to double-strand breaks appears to be particularly potent in keratinocytes, where it might serve as an early warning system for DNA damage induced by UV light or environmental toxins or for the presence of nuclear DNA viruses, which may also be detected by the DNA damage machinery ([@bib46]). A role for DNA damage factors and particularly p53 in anti-viral defense and innate immunity has been proposed, because p53 is responsive to type I interferons, can act as a restriction factor for viruses and transposons, and is in turn targeted by multiple viral evasion mechanisms ([@bib29], [@bib36], [@bib41]). Here, we link p53 activation to innate immunity, with the ATM-mediated phosphorylation of p53 at Ser15 being required for the association of p53 with a STING-containing signaling complex. Because cooperation between p53 and p65 in the transactivation of innate immune genes, including *IL-6* and *CCL20*, has been observed ([@bib34]), it remains to be investigated whether p53 acts as a transcription factor and/or has a role in NF-κB activation during the transcriptional response to etoposide.

We show that ATM, PARP-1, and IFI16 are important in the assembly of the DNA damage-induced STING complex. This raises important questions about the nature of the stimulus that drives STING activation after the recognition of double-strand breaks. Although the molecular mechanism of double-strand break recognition by ATM and the subsequent phosphorylation of p53 provide a molecular link between DNA damage and complex formation, it is unknown whether IFI16 is also involved in the recognition of DNA damage or replication stress in the nucleus. It is conceivable that IFI16's ability to bind unchromatinized (naked) stretches of dsDNA ([@bib39], [@bib44]) may contribute to the recognition of damaged DNA in the nucleus and provide a further DNA damage signal to activate STING.

The cGAS-independent activation of STING that we observe after etoposide-induced damage appears to proceed largely in the absence of the hallmarks of canonical STING activation: we do not detect STING phosphorylation at Serine 366 or translocation to peri-nuclear foci. However, low levels of STING trafficking and TBK1 activation probably occur and are important for the expression of *IFN-β* after etoposide treatment, possibly through the low-level activation of IRF3, which is required for the transactivation of the *IFN-β* promoter. The expression of NF-κB-dependent genes such as *IL-6*, however, can proceed in the absence of STING trafficking and TBK1 function, highlighting that STING undergoes a qualitatively different mode of activation under these circumstances.

We find that although both DNA damage and DNA transfection activate *IFN-β* induction, the pattern of transcription factor activation differs markedly, with etoposide treatment showing a greater extent of NF-κB activation than cytosolic DNA sensing, which predominantly activates IRF3. Hence, both treatments result in only partially overlapping patterns of STING-dependent gene induction. After DNA damage, STING-dependent NF-κB p65 activation is accomplished through the recruitment of the E3 ubiquitin ligase TRAF6. We provide evidence that TRAF6 catalyzes the assembly of K63-linked ubiquitin chains on STING, a function that is promoted by IFI16. Although TRAF6 also has ubiquitin ligase-independent roles in innate immune signaling ([@bib45]), it is likely that the assembly of K63-linked poly-ubiquitin chains on STING causes the recruitment of TAB2/3, TAK1, NEMO, and IKKα/β, in analogy to its role in NF-κB activation in other innate immune signaling cascades ([@bib48]).

The intense study of STING in DNA sensing has shown that STING is subject to a multitude of post-translational modifications, including modification with K63-, K48-, K27-, and K11-linked ubiquitin chains ([@bib9], [@bib25], [@bib40]). The precise molecular function of these modifications in the regulation of STING function has not yet been elucidated, but it is clear that several post-translational modifications of STING act together to fine-tune STING activity and allow for an appropriate and transient response. Any emerging alternative modes of STING activation are likely to be regulated by a similarly complex network of STING interaction partners and post-translational modifications that act in a stimulus- and time-dependent manner.

Studies show that the DNA damage-induced activation of NF-κB is only one example of novel downstream signaling responses that can be activated by STING. It has been shown that in addition to its now well-defined role in the IFN response, STING can promote autophagy ([@bib49], [@bib50]), apoptosis ([@bib19]), ER stress ([@bib38]), and potassium efflux leading to NLRP3-mediated inflammasome activation ([@bib16]). Although most signaling functions of STING involve cGAS and cGAMP, instances of cGAS-independent STING signaling have been described, for instance, after the recognition of viral membrane fusion ([@bib24]) and after recognition of RNA ligands by RIG-I and MDA5 ([@bib15]). The activation of STING by RIG-I-like receptors (RLRs) induces yet another downstream response in limiting the translation of viral mRNAs that, like the response to DNA damage, occurs in the absence of detectable STING translocation and phosphorylation ([@bib15]). It remains to be determined how STING is activated under these conditions and how the mode of STING activation mediates the choice of one STING-dependent signaling pathway over another. Our work provides evidence for the notion that STING is not solely an adaptor in the cytosolic DNA sensing response but rather acts a signaling hub that integrates input signals from several sensors in the cell and shapes the resulting cell-intrinsic response, depending on the type of threat.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**STING (Western, IP)Cell SignalingCat\#13647; RRID: [AB_2732796](nif-antibody:AB_2732796){#interref0010}Phospho(Ser366)-STING (Western)Cell SignalingCat\#85735p53 (Western)Cell SignalingCat\#9282; RRID: [AB_10693944](nif-antibody:AB_10693944){#intref0010}Phospho(Ser139)-H2A.X (Western)Cell SignalingCat\#2577; RRID: [AB_2118010](nif-antibody:AB_2118010){#intref0015}NF-κBp65 (Western, IF)Cell SignalingCat\#6956; RRID: [AB_10828935](nif-antibody:AB_10828935){#intref0020}Phospho(Ser536)-NF-κBp65 (Western)Cell SignalingCat\#3033; RRID: [AB_331284](nif-antibody:AB_331284){#intref0025}TBK1 (Western)Cell SignalingCat\#3504; RRID: [AB_2255663](nif-antibody:AB_2255663){#intref0030}Phospho(Ser172)-TBK1 (Western)Cell SignalingCat\#5483; RRID: [AB_10693472](nif-antibody:AB_10693472){#intref0035}IRF3 (Western, IF)Cell SignalingCat\#11904; RRID: [AB_2722521](nif-antibody:AB_2722521){#intref0040}Phospho(Ser396)-IRF3 (Western)Cell SignalingCat\#4947; RRID: [AB_823547](nif-antibody:AB_823547){#intref0045}TRAF6 (Western, IP)Cell SignalingCat\#8028; RRID: [AB_10858223](nif-antibody:AB_10858223){#intref0050}HA-tag (Western)Cell SignalingCat\#2367; RRID: [AB_331789](nif-antibody:AB_331789){#intref0055}K63-linked Ubiquitin (Western, IP)Cell SignalingCat\#5621; RRID: [AB_10827985](nif-antibody:AB_10827985){#intref0060}IFI16 (N-terminal) (Western)Santa CruzCat\#Sc-8023; RRID: [AB_627775](nif-antibody:AB_627775){#intref0065}IFI16 (C-terminal) (Western, IP)Santa CruzCat\#Sc-6050; RRID: [AB_648739](nif-antibody:AB_648739){#intref0070}cGAS (Western)Sigma PrestigeCat\#HPA031700; RRID: [AB_10601693](nif-antibody:AB_10601693){#intref0075}Histone 3Cell SignalingCat\#4499; RRID: [AB_10544537](nif-antibody:AB_10544537){#intref0080}GAPDHSanta CruzCat\#Sc-166545; RRID: [AB_2107299](nif-antibody:AB_2107299){#intref0085}AIFCell SignalingCat\#5318; RRID: [AB_10634755](nif-antibody:AB_10634755){#intref0090}β-actin (Western)SigmaCat\#A2228; RRID: [AB_476697](nif-antibody:AB_476697){#intref0095}Anti-mouse-HRP (Western)Cell SignalingCat\#7076; RRID: [AB_330924](nif-antibody:AB_330924){#intref0100}Anti-rabbit-HRP (Western)Cell SignalingCat\#7074; RRID: [AB_2099233](nif-antibody:AB_2099233){#intref0105}Anti-goat-HRP (Western)Santa CruzCat\#Sc-2020; RRID: [AB_631728](nif-antibody:AB_631728){#intref0110}Anti-mouse-AF647 (IF)Thermo FisherCat\#A21236; RRID: [AB_2535805](nif-antibody:AB_2535805){#intref0115}Anti-mouse-AF488 (IF)Thermo FisherCat\#A11029; RRID: [AB_2534088](nif-antibody:AB_2534088){#intref0120}Anti-rabbit-AF488 (IF)Thermo Fisher ScientificCat\#A11034; RRID: [AB_2576217](nif-antibody:AB_2576217){#intref0125}**Bacterial and Virus Strains**pLVX-TetOne-Puro-LucClontechCat\#631849pLVX-TetOne-Puro-IFI16This paperN/ANovaBlue Competent cellsNovagenCat\#69284**Chemicals, Peptides, and Recombinant Proteins**EtoposideSigmaCat\#E1383IodoacetamideSigmaCat\#I1149DNase IThermo ScientificCat\#EN0525Lipofectamine 2000InvitrogenCat\#11668500GeneJuiceMerckCat\#70967Herring Testis DNASigmaCat\#D6898poly(I:C)SigmaCat\#P9582PolybreneSigmaCat\#H9286PuromycinSigmaCat\#P8833DoxycyclineSigmaCat\#D9891DNA Quick Extract SolutionEpiBioCat\#QE09050Lightcycler FastStart DNA Master SYBR Green 1RocheCat\#03003230001SYBR Green PCR Master MixApplied BiosystemsCat\#43-643-46Protein G Sepharose beads 4 Fast FlowGE HealthcareCat\#GE17-0618-01Clarity ECL Western Blotting SubstrateBio-RadCat\#1705061Clarity Max ECL Western Blotting SubstrateBio-RadCat\#1705062Giemsa stainSigmaCat\#GS500MOWIOL 488CalbiochemCat\#475904ATM Inhibitor KU55933Santa CruzCat\#sc-202963TBK1 Inhibitor MRT67307MRC Protein Phosphorylation and Ubiquitylation Unit, University of DundeeN/APARP Inhibitor PJ34SigmaCat\#P4365Brefeldin AeBioscienceCat\#00-4506-51Ubc13 inhibitor NSC697923SigmaCat\#SML0618**Critical Commercial Assays**CellTox Green Cytotoxicity AssayPromegaCat\#G8741Annexin V apoptosis detection kiteBioscienceCat\#88-8005Cell Fractionation KitCell SignalingCat\#9038Human IL-6 DuoSet ELISAR&D SystemsCat\#DY206-05One-Glo Luciferase Reporter Assay SystemPromegaCat\#E6110Lightcycler480 High Resolution Melting master mixRocheCat\#04909631001EZNA total RNA KitOmega Bio-TEKCat\#R6834-02iScript cDNA Synthesis KitBio-RadCat\#170-8891RT2 First Strand MixQIAGENCat\#330401RT2 Profiler PCR Array Human Cytokines and ChemokinesQIAGENCat\#PAHS-150ZF**Deposited Data**Raw data of imagesThis paper, Mendeley Data<https://doi.org/10.17632/5vxm8rptk2.1>**Experimental Models: Cell Lines**Human: cell line HaCaTDKFZCat\#300493Human: IFI16-deficient HaCaT cells BF4[@bib3]N/AHuman: IFI16-deficient HaCaT cells 4-11[@bib3]N/AHuman: STING-deficient HaCaT cells 3-B3This PaperN/AHuman: STING-deficient HaCaT cells 3-C8This PaperN/AHuman: cGAS-deficient HaCaT cells 1-A8[@bib3]N/AHuman: cGAS-deficient HaCaT cells 2-A6This PaperN/AHuman: TRAF6-deficient HaCaT cells 22[@bib45]N/AHuman: TRAF6-deficient HaCaT cells 44[@bib45]N/AHuman: HEK293 cells expressing pGreenFire-ISREDr. Jan RehwinkelN/AHuman: cell line NHEKLonzaCat\#192627Human: cell line MRC-5Dr. Michael NevelsN/AHuman: cell line THP1ECACC; Dr. Martin JakobsenECACC 88081201; [@bib27]Human: IFI16-deficient THP1 cells[@bib27]N/AHuman: STING-deficient THP1 cells[@bib27]N/AHuman: cGAS-deficient THP1 cells[@bib27]N/A**Oligonucleotides**Non-targeting siRNA poolGE DharmaconCat\#D-001810-10-05IFI16-targeting siRNA poolGE DharmaconCat\#L-020004-00-0005STING-targeting siRNA poolGE DharmaconCat\#L-024333-02-0005cGAS-targeting siRNA poolGE DharmaconCat\#L-015607-02-0005p53-targeting siRNA poolGE DharmaconCat\#L-003329-00-0005See [Table S1](#mmc1){ref-type="supplementary-material"} for qRT-PCR primer sequencesN/AN/A**Recombinant DNA**pcDNA3: p53 WT[@bib33]Addgene 69003pcDNA3: p53 S15A[@bib33]Addgene 69004pcDNA3: p53 S15D[@bib33]Addgene 69005pcDNA3.1: IFI16-FlagThis PaperN/ApcDNA3.1: STING-FlagDR L. Jin, Albany Medical CentreN/AHA-UbiquitinA. Mansell, Monash UniversityN/ATRAF2Tularik, San FranciscoN/ATRAF3Tularik Inc., San FranciscoN/ATRAF6Tularik Inc., San FranciscoN/A**Software and Algorithms**Odyssey imaging systemLI-COR BiosciencesLI-COR BiosciencesImage LabBio-Rad<http://www.bio-rad.com/en-uk/product/image-lab-software?ID=KRE6P5E8Z>Zen Microscope softwareZeiss<https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html>OMEROUniversity of Dundee & Open Microscopy Environment<http://www.openmicroscopy.org/omero/>Magellan Data Analysis softwareTecan<https://lifesciences.tecan.com/products/software/magellan_data_analysis_software>CytExpertBeckman Coulter<https://www.beckman.com/coulter-flow-cytometers/cytoflex/cytexpert>Lightcycler software 4.1RocheCat\#04898915001SABiosciences PCR Array AnalysisQIAGEN<http://dataanalysis.sabiosciences.com/pcr/arrayanalysis.php>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Leonie Unterholzner (<l.unterholzner@lancaster.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell culture {#sec4.3.1}

Immortalized human HaCaT keratinocytes, primary MRC-5 human fibroblasts and HEK293T cells were grown in DMEM (Life Technologies) supplemented with 10% Fetal Bovine Serum (FBS; Sigma) and 50μg/mL Gentamycin (Life Technologies). Primary normal human dermal keratinocytes from adult donors (NHEK; Lonza) were grown in KGM-Gold Keratinocyte Basal Medium supplemented with KGM-Gold SingleQuots (Lonza). THP1 cells were grown in RPMI 1640 (Life Technologies) supplemented with 10% FBS and 50 μg/mL Gentamycin, and differentiated with 100nM PMA for 24h where indicated.

THP1 cells lacking STING, IFI16 or cGAS were generated using CRISPR/Cas9 ([@bib27]). HaCaT cell clones lacking TRAF6 were generated using Cas9 nickase ([@bib45]). *IFI16*^*−/−*^ HaCaT cells were generated using TALENs as described ([@bib3]). HaCaT cells lacking cGAS or STING were generated using CRISPR-Cas9 nickase. Plasmids encoding Cas9 nickase and two guide RNAs, were transfected into HaCaT cells using the Neon transfection system (Life Technologies). Cells were selected for 48h with Puromycin, and cell clones were generated by limiting dilution. Cell clones were screened for modifications of the target site, using high resolution melting analysis using LightCycler480 High Resolution Melting master mix (Roche) on a LightCycler 96 system (Roche). Candidate clones were screened by western blotting and immunofluorescence.

Method Details {#sec4.4}
--------------

### Plasmids and Transfection {#sec4.4.1}

HEK293T cells were transfected using 3μL of GeneJuice (Merck) per 1μg of plasmid DNA. p53 expression plasmids (wild-type, S15A and S15D) were obtained from the David Meek lab, University of Dundee ([@bib33]). IFI16 expression plasmid was generated by inserting the coding sequence from the *IFI16* B isoform into pcDNA3.1. pcDNA3.1:STING-FLAG was kindly provided by Lei Jin, Albany Medical Centre, the HA-ubiquitin expression construct by A. Mansell, Monash University, and TRAF6 expression plasmids were obtained from Tularik, San Francisco. Transfection for stimulation of cells with exogenous nucleic acids were performed using Lipofectamine 2000 (Thermo Fisher Scientific), using 1 μL Lipofectamine 2000 and 1 μg herring testis (HT) DNA (Sigma) or 100ng poly(I:C) (Sigma) per mL of medium.

Luciferase- and IFI16-expressing lentiviruses derived from vector pLVX-TetOne-Puro (Clontech) were generated in HEK293T cells as described ([@bib21]). Lentiviruses were added to cell media with 8μg/mL Polybrene (Sigma) and incubated for 24h, before addition of Puromycin (Sigma) selection medium. Lentiviral gene expression was activated by 24h incubation with 1μg/mL Doxycycline (Sigma).

### DNA Damaging Agents and Inhibitors {#sec4.4.2}

Etoposide and inhibitors were diluted in DMSO. Etoposide (Sigma) was used at a final concentration of 50 μM, unless indicated otherwise. ATM inhibitor KU55933 (Santa Cruz) was used at 10 μM. TBK1 inhibitor MRT67307 was kindly provided by the MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, and used at 2 μM. PARP inhibitor PJ34 (Sigma) was used at 10μM. Brefeldin A (eBioscience) was used at 3μg/mL. Ubc13 inhibitor NSC697923 (Sigma) was used at 1 and 10 μM as indicated.

### siRNAs {#sec4.4.3}

Pools of four individual siRNAs were obtained from GE Dharmacon (SMARTpool: ON-TARGETplus siRNA). Cells were transfected with 3 μL Lipofectamine RNAiMax (Thermo Fisher Scientific) per mL medium and 5nM of non-targeting siRNA pool or *IFI16*-, *STING*-, or *p53*-targeting siRNA for 48h before stimulation of cells.

### qRT-PCR {#sec4.4.4}

RNA was extracted from cells using the EZNA total RNA kit (Omega Bio-TEK), treated with DNase I (Thermo Scientific), and reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories) according to manufacturer's instructions. PCR primers were synthesized by Eurofins Genomics, for sequences see [Table S1](#mmc1){ref-type="supplementary-material"}. qRT-PCR amplification was carried out using FastStart Universal SYBR Green master mix (Roche) on a LightCycler 96 realtime PCR instrument (Roche). The cycling program was as follows: initial denaturation at 95°C for 600 s; 40 cycles of 95°C for 10 s and 60°C for 30 s; followed by a melt curve step. Quantification cycle (Cq) for the mRNAs of interest were normalized to *β-actin* reference mRNA and data was expressed as fold change over mock treatment.

For the qRT-PCR array, cDNA was prepared using RT2 First Strand Mix (QIAGEN), and amplified using RT2 SYBR Green qPCR Master Mix (QIAGEN) with the RT2 Profiler PCR Array Human Cytokines and Chemokines (PAHS-150ZF, QIAGEN), according to manufacturer's instructions. Data was analyzed using SABioscience PCR array analysis software.

### ELISA and IFN Bio-assay {#sec4.4.5}

Secreted interleukin-6 (IL-6) protein in cell supernatants was quantified using the Human IL-6 DuoSet ELISA (R&D Systems) according to manufacturer's instructions. Results were expressed as pg/mL IL-6 protein in supernatants, based on a standard curve from recombinant IL-6 standards. Bio-active type I IFN in cell supernatants was measured using an IFN bioassay utilizing HEK293 cells stably expressing a pGreenFire-ISRE construct (kindly provided by Jan Rehwinkel). Reporter cells were overlaid with sample cell culture supernatant for 24h, and luminescence was measured using One-Glo Luciferase Assay System (Promega) according to manufacturer's instructions.

### Immunoblotting {#sec4.4.6}

Cells were lysed in Mammalian Cell Lysis Buffer (50mM Tris-Cl pH 7.5, 1mM EDTA, 1mM EGTA, 1% (v/v) Triton X-100, 1mM sodium orthovanadate, 50mM sodium fluoride, 5mM sodium pyrophosphate, 10mM sodium β-glycerophosphate, 0.27M sucrose, 0.1% (v/v) 2-mercaptoethanol, 0.1mM PMSF, 10 μl/ml Aprotinin) and pre-cleared by centrifugation at 8,000xg for 10 min. In the fractionation experiments, subcellular fractions were separated using the Cell Fractionation kit (Cell Signaling) according to manufacturer's instructions. Pre-cleared lysates were denatured by boiling in SDS sample buffer (62.5mM Tris-Cl pH 6.8, 2% (w/v) SDS, 10% Glycerol, 0.1% Bromophenol Blue, 50mM DTT). Proteins were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore) using semi-dry transfer (Biometra). Membranes were blocked with 5% (w/v) non-fat milk, or 5% bovine serum albumin (BSA), in 0.1% Tween-20/TBS for 1h. Primary antibodies were used at a dilution of 1:1000. Secondary HRP-coupled antibodies were used at 1:3000. Membranes were developed using Clarity or Clarity Max ECL substrate (Bio-Rad) and imaged on a Chemidoc (Bio-Rad) or Odyssey (LI-COR) imaging system.

### Co-Immunoprecipitation {#sec4.4.7}

Cells were lysed in Mammalian Cell Lysis Buffer (50mM Tris-Cl pH 7.5, 1mM EDTA, 1mM EGTA, 1% (v/v) Triton X-100, 1mM sodium orthovanadate, 50mM sodium fluoride, 5mM sodium pyrophosphate, 10mM sodium β-glycerophosphate, 0.27M sucrose, 0.1% (v/v) 2-mercaptoethanol, 0.1mM PMSF, 10 μL/mL Aprotinin). For the immunoprecipitation of ubiquitin chains, the lysis buffer was supplemented with 50mM iodoacetamide (Sigma). Samples were pre-cleared by centrifugation at 8,000xg for 10 min before incubation with 1 μL of antibodies overnight at 4°C, followed by the addition of a 30 μL protein G beads (Thermo Fisher) for 3h at 4°C. Beads were washed three times with lysis buffer and bound proteins were eluted by boiling in SDS sample buffer for 10 min. A portion of each whole cell lysate was retained as input controls.

### Confocal Microscopy {#sec4.4.8}

For staining of NF-κB p65, cells grown on glass coverslips were fixed for 15 min in 4% paraformaldehyde, and permeabilised for 12 min in 0.5% Triton X-100/PBS. Coverslips were incubated in blocking buffer (5% BSA in 0.05% Tween-20/PBS) for 1h, and stained overnight with primary antibodies (1:600), washed with PBS, and incubated with fluorescently labeled secondary antibodies (1:1500) for 3h. For visualization of STING, cells were fixed in methanol at −20°C, permeabilised, and incubated with blocking buffer containing 5% FBS in 0.05% Tween-20/PBS before incubation with antibodies as above. Coverslips were mounted in MOWIOL 4-88 (Calbiochem) containing 1 μg/mL DAPI (Sigma). Images were taken on a Zeiss LSM880 confocal microscope.

### Cytotoxicity Assays {#sec4.4.9}

Cells were seeded in 96 well plates and treated as indicated. Cyanine Dye and Assay Buffer from CellTox Green Cytotoxicity Assay (Promega) were incubated with cells for 15 min after treatment. Fluorescence was measured using the Infinite M200 PRO (Tecan) plate reader at wavelengths of 485-500nmEx/520-530nmEm.

Cells undergoing apoptosis were quantified using the Annexin V apoptosis detection kit (eBioscience). Cells were treated with Etoposide for the indicated times, then washed and stained with Annexin V and Propidium Iodide according to manufacturer's instructions. Cells were analyzed by flow cytometry (Cytoflex, Beckman Coulter).

### Clonogenic Survival Assay {#sec4.4.10}

Cells were seeded in 6 well plates and allowed to attach prior to treatment with indicated concentrations of Etoposide. Media was changed after 24 h, and cells were allowed to grow for for a further 14 days. Cells were then washed, fixed, and stained with Giemsa stain (Sigma). The number of colonies containing \> 50 cells was counted. Cell viability of untreated cells was treated as 100%.

### cGAMP Detection by LC-MS {#sec4.4.11}

cGAMP detection was carried out as described in Almine et al., 2017. Cells were lysed in cold 80% methanol, and an internal standard of 0.45pmol cyclic di-AMP was added to each sample. Samples then underwent three rounds of butanol:water extraction. Dried samples were resuspended in 1mL H~2~O and purified by solid phase extraction using HyperSep Aminopropyl columns (Thermo Scientific). Columns were washed twice with 2% (v/v) acetic acid and 80% (v/v) methanol. Elution was performed using 4% (v/v) ammonium hydroxide and 80% (v/v) methanol. Samples were resuspended in 50 μL H~2~O for analysis. cGAMP levels were measured by liquid chromatography mass spectrometry (LC-MS) using a TSQ Quantiva interfaced with Ultimate 3000 Liquid Chromatography system (Thermo Scientific), equipped with a porous graphitic carbon column (HyperCarb 30x1mm ID 3 μm; Part No: C-35003-031030, Thermo-Scientific). cGAMP and cyclic di-AMP levels were measured using multiple reaction monitoring mode (MRM) with optimized collision energies. Three transitions (328.03, 343.92 and 522.00) were used to monitor cGAMP and one transition (328.03) was used to detect cyclic di-AMP.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Quantitative data are expressed as mean of biological triplicate samples ± SD. Data were subjected to a multiple t test statistical analysis with the Holm-Sidak method. ^∗^ p \< 0.05, ^∗∗^ p \< 0.01, ^∗∗∗^ p \< 0.001, as indicated in the figure legends.

Data and Software Availability {#sec4.6}
------------------------------

Raw data have been deposited to Mendeley Data and are available at <https://doi.org/10.17632/5vxm8rptk2.1>.
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